Literature DB >> 25950011

Molecular Inclusion Complexes of β-Cyclodextrin Derivatives Enhance Aqueous Solubility and Cellular Internalization of Paclitaxel: Preformulation and In vitro Assessments.

Milin Shah1, Vatsal Shah1, Anasuya Ghosh1, Zheng Zhang2, Tamara Minko1.   

Abstract

Drugs with low aqueous solubility and permeability possess substantial challenges in designing effective and safe formulations. Synergistic solubility and permeability enhancement in a simple formulation can increase bioavailability and efficacy of such drugs. To overcome limitations of the clinical formulation of Taxol®, Paclitaxel (PTX) was reformulated with various β-cyclodextrin (CD) derivatives suitable for parenteral administration. Results indicated that β-CDs can efficiently form complexes with PTX at lower molar ratios, enhance aqueous solubility up to 500 times and improved cellular internalization of PTX. All β-CD derivatives were found to be safe as excipient since none showed detectable signs of cyto-genotoxicity. As a result, the CD-PTX complexes significantly increased the cytotoxicity of the drug. The study concluded that CD-PTX formulations could substitute the current intravenous infusion of PTX obviating the use of non-inert excipient Cremophor EL.

Entities:  

Keywords:  Compounds; Cyclodextrins; Enhancement; Inclusion; Permeability enhancement; Preformulation; Solubility

Year:  2015        PMID: 25950011      PMCID: PMC4418459          DOI: 10.13188/2327-204X.1000011

Source DB:  PubMed          Journal:  J Pharm Pharmacol (Los Angel)


  18 in total

Review 1.  Pharmacogenomics of paclitaxel.

Authors:  Cristina Rodríguez-Antona
Journal:  Pharmacogenomics       Date:  2010-05       Impact factor: 2.533

2.  Bivalent sequential binding of docetaxel to methyl-β-cyclodextrin.

Authors:  Silvia Mazzaferro; Kawthar Bouchemal; Jean-François Gallard; Bogdan I Iorga; Monique Cheron; Claire Gueutin; Claire Steinmesse; Gilles Ponchel
Journal:  Int J Pharm       Date:  2011-06-25       Impact factor: 5.875

3.  Preparation, characterization, molecular modeling and in vitro activity of paclitaxel-cyclodextrin complexes.

Authors:  Stefano Alcaro; Cinzia Anna Ventura; Donatella Paolino; Danilo Battaglia; Francesco Ortuso; Luigi Cattel; Giovanni Puglisi; Massimo Fresta
Journal:  Bioorg Med Chem Lett       Date:  2002-06-17       Impact factor: 2.823

4.  Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.

Authors:  U S Sharma; S V Balasubramanian; R M Straubinger
Journal:  J Pharm Sci       Date:  1995-10       Impact factor: 3.534

5.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

6.  Interaction of taxol and other anticancer drugs with alpha-cyclodextrin.

Authors:  T Cserháti; E Forgács; J Holló
Journal:  J Pharm Biomed Anal       Date:  1995-04       Impact factor: 3.935

Review 7.  Cyclodextrins.

Authors:  Valentino J Stella; Quanren He
Journal:  Toxicol Pathol       Date:  2008-01       Impact factor: 1.902

Review 8.  Self-association of cyclodextrins and cyclodextrin complexes.

Authors:  Thorsteinn Loftsson; Már Másson; Marcus E Brewster
Journal:  J Pharm Sci       Date:  2004-05       Impact factor: 3.534

9.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

10.  Mass spectrometry and molecular modeling studies on the inclusion complexes between alendronate and β-cyclodextrin.

Authors:  Joanna Biernacka; Katarzyna Betlejewska-Kielak; Janina Witowska-Jarosz; Ewa Kłosińska-Szmurło; Aleksander P Mazurek
Journal:  J Incl Phenom Macrocycl Chem       Date:  2013-04-17       Impact factor: 1.633

View more
  5 in total

1.  Preparation and Properties of Cyclodextrin Inclusion Complexes of Hyperoside.

Authors:  Xinyu Zhang; Jianqing Su; Xiaoya Wang; Xueyan Wang; Ruixue Liu; Xiang Fu; Ying Li; Jiaojiao Xue; Xiaoli Li; Rui Zhang; Xiuling Chu
Journal:  Molecules       Date:  2022-04-25       Impact factor: 4.927

Review 2.  A Promising Review on Cyclodextrin Conjugated Paclitaxel Nanoparticles for Cancer Treatment.

Authors:  Kamini Velhal; Sagar Barage; Arpita Roy; Jaya Lakkakula; Ramesh Yamgar; Mohammed S Alqahtani; Krishna Kumar Yadav; Yongtae Ahn; Byong-Hun Jeon
Journal:  Polymers (Basel)       Date:  2022-08-03       Impact factor: 4.967

3.  Molecular Structure of Cefuroxime Axetil Complexes with α-, β-, γ-, and 2-Hydroxypropyl-β-Cyclodextrins: Molecular Simulations and Raman Spectroscopic and Imaging Studies.

Authors:  Barbara Gieroba; Grzegorz Kalisz; Anna Sroka-Bartnicka; Anita Płazińska; Wojciech Płaziński; Małgorzata Starek; Monika Dąbrowska
Journal:  Int J Mol Sci       Date:  2021-05-15       Impact factor: 5.923

4.  Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery.

Authors:  Gamze Varan; Juan M Benito; Carmen Ortiz Mellet; Erem Bilensoy
Journal:  Beilstein J Nanotechnol       Date:  2017-07-13       Impact factor: 3.649

5.  Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.

Authors:  Shinichi Saito; Yoshihiro Koya; Hiroaki Kajiyama; Mamoru Yamashita; Fumitaka Kikkawa; Akihiro Nawa
Journal:  Cancer Sci       Date:  2020-04-03       Impact factor: 6.716

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.